Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Boutique is (again) chic

Bigger is better, except when you're a bulge bracket bank in a bear market. Thus, the effects of the bust cycle may make room once again for boutique investment banks.

Last week, a boutique franchise returned to the biotech fold. Vector Securities came out from under the rock (Prudential) to announce it has formed a separate

Read the full 562 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers